Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial

Ippolito, Edy; Cellini, Numa; Digesù, Cinzia; Cilla, Savino; Mantini, Giovanna; Boccadoro, Mario; Lallo, Alessandra Di; Deodato, Francesco; Macchia, G.; Massaccesi, Mariangela; Mattiucci, Gian Carlo; Tagliaferri, Luca; Piermattei, Angelo; Cuscunà, Daniele; Morganti, Alessio Giuseppe

doi:10.1016/j.urolonc.2010.10.005

Cited by 19 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventeen eligible studies were included. (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35) These retrospective (20, 23-25, 27, 30, 34) [7] and prospective (19,21,22,26,28,29,(31)(32)(33)35) [10] trials had heterogeneous characteristics in terms of dose, target definition and combination with hormonal therapy. Median follow-up ranged between 11.5 and 111.0 months (median: 30.0 months).…”

Section: Resultsmentioning

confidence: 99%

Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review

Siepe

Buwenge

Nguyen

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review

Siepe

Buwenge

Nguyen

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For example, a series of our parallel studies showed that the use of postoperative IMRT significantly reduces rectum and bladder irradiation compared to 3D RT [28]. In addition, hypofractionated high-dose IMRT delivered with simultaneous integrated boost (SIB) enables reduction of the overall treatment time, with an acute toxicity profile which compares favourably with that of conventionally fractionated high-dose 3D RT [29, 30]. …”

Section: Discussionmentioning

confidence: 99%

Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial

Mantini

Fersino

Alitto

et al. 2014

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Purpose. To perform a preliminary feasibility acute and late toxicity evaluation of an intensified and modulated adjuvant treatment in prostate cancer (PCa) patients after radical prostatectomy. Material and Methods. A phase I/II has been designed. Eligible patients were 79 years old or younger, with an ECOG of 0–2, previously untreated, histologically proven prostate adenocarcinoma with no distant metastases, pT2–4 N0-1, and with at least one of the following risk factors: capsular perforation, positive surgical margins, and seminal vesicle invasion. All patients received a minimum dose on tumor bed of 64.8 Gy, or higher dose (70.2 Gy; 85.4%), according to the pathological stage, pelvic lymph nodes irradiation (57.7%), and/or hormonal therapy (69.1%). Results. 123 patients were enrolled and completed the planned treatment, with good tolerance. Median follow-up was 50.6 months. Grade 3 acute toxicity was only 2.4% and 3.3% for genitourinary (GU) and gastrointestinal (GI) tract, respectively. No patient had late grade 3 GI toxicity, and the GU grade 3 toxicity incidence was 5.8% at 5 years. 5-year BDSF was 90.2%. Conclusions. A modulated and intensified adjuvant treatment in PCa was feasible in this trial. A further period of observation can provide a complete assessment of late toxicity and confirm the BDSF positive results.

show abstract

“…There are two Italian studies on adjuvant radiotherapy with a hypofractionated scheme [23,24]; . No dose-limiting toxicity was seen at a median follow-up time of 19 months and therefore the recommended dose was 62.5 Gy in 2.5 Gy/ fraction [24]. In 2008 Cozzarini et al also reported on hypofractionated adjuvant radiotherapy of 50 patients, using helical tomotherapy.…”

Section: Adjuvant or Salvage Hypofractionated Radiotherapymentioning

confidence: 99%

“…Until now, several prospective and retrospective trials have been published [24,[29][30][31][32][33][34] on hypofractionated treatment of the prostate/prostate bed with simultaneous conventionally fractionated irradiation of the pelvic lymph nodes ( Table 3). So far apart from the above mentioned and currently accruing trial on hypofractionated irradiation of pelvic lymph nodes, no study has been published so far on hypofractionation in pelvic lymph nodes' treatment.…”

Section: Hypofractionated Radiotherapy With Pelvic Lymph Node Irradiamentioning

confidence: 99%

Hypofractionated radiotherapy for prostate cancer

et al. 2014

View full text Add to dashboard Cite

In the last few years, hypofractionated external beam radiotherapy has gained increasing popularity for prostate cancer treatment, since sufficient evidence exists that prostate cancer has a low α/β ratio, lower than the one of the surrounding organs at risk and thus there is a potential therapeutic benefit of using larger fractionated single doses. Apart from the therapeutic rationale there are advantages such as saving treatment time and medical resources and thereby improving patient's convenience. While older trials showed unsatisfactory results in both standard and hypofractionated arm due to insufficient radiation doses and non-standard contouring of target volumes, contemporary randomized studies have reported on encouraging results of tumor control mostly without an increase of relevant side effects, especially late toxicity. Aim of this review is to give a detailed analysis of relevant, recently published clinical trials with special focus on rationale for hypofractionation and different therapy settings.

show abstract

Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial

Cited by 19 publications

References 34 publications

Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review

Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review

Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial

Hypofractionated radiotherapy for prostate cancer

Contact Info

Product

Resources

About